18th July 2019
Functional constipation in childhood is very common. The spectrum ranges from mild to severe and intractable, requiring hospitalisation and possible surgery for management. It can markedly impair quality of life, with further effects on the child’s social functioning.
Despite the prevalence of paediatric constipation, its aetiology is still poorly understood. Transit tests have become a valuable part of the evaluation of children with functional constipation, but are not performed routinely mainly due to the limitations of the current tests. There is an unmet need for a widely applicable, non-ionising radiation method to provide objective measurements of gastrointestinal transit in young patients. Magnetic resonance imaging (MRI) could provide the solution.
We have developed a new device to measure gut transit in paediatric constipation. The device consists of small, inert mini-capsules made of plastic that, once ingested, can be imaged inside the gastrointestinal tract using MRI, creating a MRI alternative to the radiopaque marker X-ray test to measure gut transit.
We now want to test the ability of the device to measure transit before and after treatment for intractable constipation in 25 children. These results will be compared to 25 age matched healthy controls who do not present with constipation.
Follow the MAGIC journey through the study website: www.gastrointestinalmri.org.uk
11th July 2019
Huge congratulations to Dr Neil Guha and Andy Wragg for being recognised for their hard work at the R&I NUH Research and Excellence Awards 2018/19 on Thursday 11th July 2019. The event took place after the Nottingham BRC Annual Conference and was hosted by Dr Maria Koufali, Managing Director, Research and Innovation.
Dr Neil Guha was presented with the ‘Research Excellence - Impact and Outcome’ award.
Andy Wragg was presented with the ‘Innovation in Patient and Public Involvement/Engagement’ award.
Both awards very well deserved!!
18th June 2019
Huge congratulations to Dr Jane Chalmers & The Scarred Liver Project team who were awarded the BSG Clinical Services & Standards Committee Service Development Prize 2019 for “the development of a new diagnostic pathway to detect chronic liver disease across primary and secondary care”.
Jane accepted the prize at the BSG Plenary session in June by Dr Cathryn Edwards and Dr Tony Tham.
Well done team!
The article outlining the development and results from the first year of the pathway has been published online in Frontline Gastroenterology
15th June 2019
One of our Patient Advisory Group (PAG) members, Clare Hutton, was featured on the BBC Panorama programme in June. Clare spoke of her life condition. Alcohol-related Liver Disease (ALD), as part of an investigation by the programme about the lack of clarity and knowledge around alcohol units, lack of information on labelling and by the industry in general.
A feature on Clare’s story can be found on the BBC website
15th June 2019
Dr Luca Marciani and the Nottingham BRC GI & Liver Disorders team hosted a fantastic Teddy Bear MRI Scanner and Endoscopy box at the University of Nottingham Wonder community event on Saturday 15th June 2019. The event is ran annually and took place throughout the University of Nottingham campus.
Thank you to everyone who came by to visit our stand and a massive well done to all the team who helped organise.
We hope everyone had a great time!
Here are a few photos of our Endoscopy in a box stand. We had a visit from Pro-Vice Chancellor Professor John Atherton!
6th June 2019
Congratulations to Professor Will Irving for receiving the BASL Recognition of Service Award 2019 for his contributions made to Hepatitis C research!
The award was presented to Will at the BASL Basic Science Retreat at The Hayes Conference Centre on 6th June by Professor Matthew Cramp. Well done Will!
23rd May 2019
Huge congratulations to Dr Neil Guha and the Scarred Liver Project team who won the ‘Improving the Value of Diagnostic Services Award’ at the HSJ Value Awards 2019! Angela, Mary, Tracey and Becky attended the awards which took place in Manchester on 23rd May. Well done team!
17th April 2019
INNOVATIVE MEDICINES INITIATIVE LAUNCHES TRANSLATIONAL SAFETY BIOMARKER PIPELINE PROJECT TO ENABLE DEVELOPMENT AND IMPLEMENTATION OF NOVEL SAFETY BIOMARKERS
The Innovative Medicines Initiative (IMI) today announced the launch of the Translational Safety Biomarker Pipeline (TransBioLine) Project, a five-year program to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular, and central nervous system) for application in drug development.
The TransBioLine Project is a consortium of 27 partners across pharmaceutical companies, small and medium-sized enterprises, and academic institutions from 10 European countries, and is coordinated by the University of Zurich with Pfizer Inc. as the industry lead. It is funded by the IMI Joint Undertaking as a public-private partnership, with a budget of 28M€ and will be active through 2024.
“One of the major gaps in drug development is the lack of qualified safety biomarkers with acceptable precision and accuracy for safety monitoring during clinical development,” said Shashi Ramaiah, Executive Director, Pfizer Drug Safety Research & Development and TransBioLine Lead Scientist. “The TransBioLine Project provides a unique opportunity to access a large expert and knowledge network, including data and samples from clinical trials, to enable the global safety qualification of identified novel biomarkers. Implementing qualified safety biomarkers in early clinical trials will mitigate safety attrition of promising drug candidates and advance projects to clinics through higher-quality and better-informed decision making.”
Michael Merz, Consortium Coordinator, University of Zurich, said, “This is one of the largest public-private partnerships of European and American scientists that focuses on the development and regulatory qualification of new safety biomarkers. These include indicators of tissue damage like liquid biopsy, biomarkers that could facilitate patient stratification, and standardized tests for detection of these biomarkers. These new markers are ultimately expected to not only improve safety of new and approved drugs, but also to contribute to better diagnosis and management of acute and chronic diseases. It is really exciting to see years of enthusiastic preparation translating into this project going forward now.”
When the project ends in 2024, the consortium will have established an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, and it will be able to provide the scientific community, industry and patients with detailed data and information across a large spectrum of advanced safety biomarkers.
Professor Guruprasad Aithal, the Deputy Academic Co-ordinator for TransBioLine and the ‘Drug-induced liver injury (DILI)’ work package lead, said- ‘TransBioLine is an enormous opportunity to turn science into clinical practice to improve safe use of medication. It will boost NIHR Nottingham BRC researchers who have led discoveries in DILI field over the past 2 decades’.
Doctors Jane Grove and Stuart Astbury are contributing to the discovery and evaluation of new tests to identify liver injury early and reduce patient harm; Ms Beth Robinson will be project coordinator for the DILI work package.
About the Innovative Medicines Initiative
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need.
More info on IMI: www.imi.europa.eu
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA companies.
24th March 2019
Could a commonly-prescribed anti-sickness drug be the answer for the 1.3 million people in the UK who suffer the pain and misery of irritable bowel syndrome with diarrhoea (IBS-D)?
A nationwide clinical trial, TRITON, led by Professor Robin Spiller in Nottingham will assess the medication ondansetron, which is currently used by doctors to help cancer patients cope with the nausea and vomiting associated with chemotherapy, radiotherapy and surgery.
The research will aim to establish whether a much lower dose of the drug could also be a successful treatment for the abdominal pain and urgent bowel movements typically experienced by IBS patients. Read the full press release on the University of Nottingham’s website
The TRITON study has also been featured in the Mail on Sunday Karen Andrews, Patient Advisory Group (PAG) member, shared her story as one of the first patients to benefit from the study.
If you would like to know more about the TRITON study and see if you are eligible to take part, please contact Dr David Gunn: David.Gunn@nottingham.ac.uk 0115 970 9966
18th February 2019
About 1% of the UK population is likely to be hospitalised in their lifetime due to the condition. But scientists don’t know what causes it.
“If you do postmortems on people, 40% of 65- to 74-year-olds will have diverticulosis, and many of them will never have had any symptoms.”
Professor Robin Spiller talks to The Guardian all about Diverticulitis and his research. Read the article on The Guardian website